Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Pulmonary embolism (PE) remains a major contributor to global disease burden. Risk-
adapted treatment and follow-up contributes to a favorable outcome. Age-adjusted cutoff …

Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite
outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients …

The heparins, well-known for their anticoagulant properties, may also have anti-
inflammatory effects that could contribute to their effectiveness in the treatment of venous …

International and national guidelines recommend low-molecular-weight heparin for the
treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the …

Background Venous thromboembolism occurs commonly in patients with cancer. Direct oral
anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous …

Thrombosis is a leading cause of death and disability worldwide, and anticoagulants are the
mainstay of its prevention and treatment. Starting with unfractionated heparin (UFH) and …

Background The safety and efficacy of edoxaban and dalteparin is unclear for several
cancer groups. Methods We evaluated the occurrence of the primary outcome in large …

Venous thromboembolism occurs in up to one-third of patients with primary brain tumors.
Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients …